Skip to content

Role of Homoeopathic Medicine In The Treatment of Benign Prostatic Hyperplasia

Role of Individualised Homoeopathic Medicine Using Fifty Millesimal Potency In The Treatment of Benign Prostatic Hyperplasia: An Open Label Clinical Study - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067640
Enrollment
35
Registered
2024-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Individualised Homoeopathic Medicine in fifty millesimal potency: Intervention is planned as to administer indicated individualised homoeopathic medicine in ascending fifty millesimal p

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: A) Patients of age group of 40-80 years B) Patients presenting symptoms of Benign prostatic hyperplasia with or without evidence of bladder outflow obstruction with AUASS more than 7 C) Patient suffering from cases of Benign Prostatic Hyperplasia diagnosed radiologically (USG Pelvis) and Ultrasonographic examination of prostate weight more than 20 g or 20 cc and RUV of more than 30ml D) Male patients of all religions and of different socioeconomic status E) Patients with known but controlled systemic diseases F) Patients who are willing to give consent to participate in the study G) Patient who can read and/or understand Hindi or Bengali or English

Exclusion criteria

Exclusion criteria: A) Patients with Serum Prostate specific antigen (PSA) more than 4 nmol per mL to rule out suspected prostatic malignancy B) Cases suffering from uncontrolled systemic illness or life-threatening conditions C) Patient suffering from complete retention of urine for more than 24hrs D) Patient having any psychiatric illness

Design outcomes

Primary

MeasureTime frame
AMERICAN UROLOGICAL ASSOCIATION Symptom Score (AUASS)Timepoint: Baseline, 3rd month and 6th month

Secondary

MeasureTime frame
USG for prostate size and residual urine volumeTimepoint: Baseline and 6th month

Countries

India

Contacts

Public ContactProf Dr Subhas Singh

National Institute of Homoeopathy

drssubhas@gmail.com9830644223

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026